COVID-19 convalescent plasma
Identification
- Name
- COVID-19 convalescent plasma
- Accession Number
- DB15692
- Description
COVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2.2 This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305), and use for single patients through an emergency IND (eIND; 21 CFR 312.310).2
Although there are no formal clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest that convalescent plasma transfusion in COVID-19 patients is safe.1
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Convalescent plasma (COVID-19)
Pharmacology
- Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Indication
- Not Available
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- YM6LN8TU2V
- CAS number
- Not Available
References
- General References
- Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas AM, Wiggins CC, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW, Lesser ER, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Hodge DO, Kunze KL, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van Buskirk CM, Winters JL, Stubbs JR, Paneth NS, Verdun NC, Marks P, Casadevall A: Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020 Jun 11. pii: 140200. doi: 10.1172/JCI140200. [PubMed:32525844]
- FDA recommendations for investigational COVID-19 convalescent plasma [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Active Not Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 3 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 3 Not Yet Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID19 Pneumonia 1 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID / COVID - 19 1 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID / COVID - 19 / Infections, Coronavirus / Viral Pneumonia 1 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / COVID / COVID - 19 / Infectious Diseases 1 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus / RNA Virus Infections / Virus Diseases 1 3 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / SARS-CoV-2 Infection (COVID-19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created on June 16, 2020 20:31 / Updated on June 17, 2020 22:27